An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : Pasireotide LAR
Phase: Phase 2
Ages Eligible For Study:
- Male and Female Patients at least 18 years old - Patient who have rare tumors of neuroendocrine origin, such as tumors of the: 1. pancreas 2. pituitary glands 3. Nelson syndrome 4. ectopic-ACTH secreting tumor - Patients who have failed standard of care treatment or for whom no standard of care treatment exist - Signed Informed Consent